Enantis (jointly with Loschmidt Laboratories) is looking for a motivated candidate for the position of Programmer / IT specialist to join our expanding bioinformatics team.
FGF2-STAB® Patent Granted in Japan
Meet Enantis: Part 8 – Ezequiel
Enantis would like to welcome its new team member Ezequiel Iván Juritz, who has joined the company as a CTO. Ezequiel is highly skilled protein design specialist who will help our growing numbers of customers with protein engineering service projects. Also, he will work on new target molecules for our pipeline.
You can read more about Ezequiel in the LinkedIn interview.
Welcome Ezequiel!
3RD HANDS-ON COMPUTATIONAL ENZYME DESIGN COURSE
Would you like to delve deeper into protein engineering?
Loschmidt Laboratories together with Enantis organize an interactive hands-on course exploring web-based tools suitable for mining new enzymes and engineering enzyme activity, specificity, enantioselectivity, stability, and solubility.
You will have a chance to learn from the developers of these tools, set up optimal calculations and interpret the results adequately. At the end of this 3-day course, you will be able to design different properties of proteins for your academic research or commercial applications.
Interested? Sign up here:
We still have free slots but the early-bird discount expires in 2 weeks. Do not miss the opportunity and apply now!
Day out for Enantis
Enantis team enjoyed a nice day out at Clubco, Vlnena. This lovely venue has been selected to provide us with a change of environment and create a nice setting to discuss our long-term strategic goals from a new perspective. We are now recharged and ready for any upcoming challenges.
New job opening at Enantis!
We are hiring again. This time, we are on the lookout for a new laboratory technician.
Advert in Czech language only.
Get in touch if you are interested and join our Protein Pro Team.
The Future of Protein Production Summit
Enantis is going to participate at the Future of protein production summit that takes place online between 8th and 10th March 2022.
We would like to use this opportunity to offer our FGF2-STAB to cultured meat companies and cultured meat media developers as an innovative and highly effective media ingredient. If you are interested in our solution, get in touch.
Merry Christmas and Happy New Year
As a closure of an eventful year, Enantis would like to wish a Merry Christmas and a Happy New Year to all our customers, collaborators, supporters and friends!
In 2021, we have reached many important milestones. We have closed new licensing deals securing a global presence of our products on the stem cell culture market. Moreover, we have manufactured record volumes of FGF2-STAB to supply our exclusive distributor and launched a new product, FGF10-STAB. Also, we have maintained our ISO 9001:2016 certification that assures well-managed quality management system in our company and started to explore new markets for our products
We are really proud of our achievements and hope this is just a start and even greater things will happen in 2022. Thank you for your support.
EIT Health Catapult
It’s been a blast! Even though we have not made it into finals, we are really proud and grateful for the opportunity to be a part of the EIT Health Catapult 2021. It has been an amazing experience and importantly, we had a chance to meet other promising biotech companies from all around Europe – AddaxBiosciences, APLEX Bio SideROS , Asylia Diagnostics BV, Bioadhesive Ophthalmics, Finnadvance, Limula, myNEO – Personalised platform for cancer, OmicEra Diagnostics, Onena Medicines Renovos Biologics Limited, ARTHEx Biotech and SolasCure.
Big shout out to the organisers and huge congratulations to the companies selected to proceed to the final round from all three categories – Biotech, Medtech and Digital Health
Onena Medicines, SideROS , SolasCure, ARTHEx Biotech, Asylia Diagnostics BV, Limula, myNEO – Personalised platform for cancer, Leuko, Luminate Medical , ThinkSono, ArthroSave B.V., BeFC Bioenzymatic Fuel Cells FeelTect, ORIXHA, AZmed, Brightlobe, Ebenbuild, Amara Therapeutics, Exheus, Heaxel and mentalis.
FGF10-STAB® GOES GLOBAL
Enantis has entered into a global supply agreement with one of the top providers of life science solutions with our innovative FGF10-STAB®. This novel, engineered protein protected by a patent is now entering the research and cell therapy market.
This is the second global supply agreement Enantis has in place. The first one covers the distribution of FGF2-STAB® molecule and we hope the new contract will bring similar business success.
Under the terms of agreement, Enantis will exclusively supply the laboratory reagents provider with FGF10-STAB® to assure worldwide accessibility of this molecule to the scientific community.
Enantis is excited to announce that our patent family has been extended by the Japanese Patent covering the hyper stable form of FGF2 (FGF2-STAB®, FGF2-G3) that has just been granted to Enantis and Masaryk University. We have worked really hard to get here. We are awaiting grant in other territories to reach broad IP protection for our unique invention.
#intellectualproperty #patent #biotechnology #innovation #research #healthcare